X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA CIPLA ELDER PHARMA/
CIPLA
 
P/E (TTM) x -0.2 40.6 - View Chart
P/BV x 0.1 3.7 2.7% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ELDER PHARMA   CIPLA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
CIPLA
Mar-18
ELDER PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs380663 57.3%   
Low Rs188479 39.2%   
Sales per share (Unadj.) Rs491.2189.0 259.8%  
Earnings per share (Unadj.) Rs-3.217.6 -18.1%  
Cash flow per share (Unadj.) Rs14.434.0 42.3%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs376.5176.7 213.0%  
Shares outstanding (eoy) m20.54805.12 2.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.63.0 19.1%   
Avg P/E ratio x-89.332.5 -275.1%  
P/CF ratio (eoy) x19.716.8 117.5%  
Price / Book Value ratio x0.83.2 23.3%  
Dividend payout %017.1 0.0%   
Avg Mkt Cap Rs m5,833459,724 1.3%   
No. of employees `000NA23.6 0.0%   
Total wages/salary Rs m2,17926,901 8.1%   
Avg. sales/employee Rs ThNM6,446.1-  
Avg. wages/employee Rs ThNM1,139.4-  
Avg. net profit/employee Rs ThNM600.0-  
INCOME DATA
Net Sales Rs m10,089152,193 6.6%  
Other income Rs m2573,577 7.2%   
Total revenues Rs m10,346155,769 6.6%   
Gross profit Rs m-79228,264 -2.8%  
Depreciation Rs m36113,228 2.7%   
Interest Rs m2,7561,142 241.3%   
Profit before tax Rs m-3,65317,470 -20.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m3,713-775 -478.9%   
Tax Rs m1252,501 5.0%   
Profit after tax Rs m-6514,166 -0.5%  
Gross profit margin %-7.818.6 -42.3%  
Effective tax rate %-3.414.3 -23.9%   
Net profit margin %-0.69.3 -7.0%  
BALANCE SHEET DATA
Current assets Rs m9,240108,141 8.5%   
Current liabilities Rs m9,99838,322 26.1%   
Net working cap to sales %-7.545.9 -16.4%  
Current ratio x0.92.8 32.8%  
Inventory Days Days4697 47.7%  
Debtors Days Days6074 80.6%  
Net fixed assets Rs m10,124109,411 9.3%   
Share capital Rs m2061,610 12.8%   
"Free" reserves Rs m5,582140,682 4.0%   
Net worth Rs m7,734142,292 5.4%   
Long term debt Rs m4,88936,621 13.4%   
Total assets Rs m22,882228,606 10.0%  
Interest coverage x-0.316.3 -2.0%   
Debt to equity ratio x0.60.3 245.6%  
Sales to assets ratio x0.40.7 66.2%   
Return on assets %11.86.7 175.6%  
Return on equity %-0.810.0 -8.5%  
Return on capital %22.310.0 224.1%  
Exports to sales %3.032.8 9.3%   
Imports to sales %0.40-   
Exports (fob) Rs m30749,883 0.6%   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30751,691 0.6%   
Fx outflow Rs m12521,033 0.6%   
Net fx Rs m18130,658 0.6%   
CASH FLOW
From Operations Rs m11,75414,628 80.4%  
From Investments Rs m-561-8,540 6.6%  
From Financial Activity Rs m-6,762-3,855 175.4%  
Net Cashflow Rs m4,4322,431 182.3%  

Share Holding

Indian Promoters % 39.6 16.0 247.5%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 7.5 12.2 61.5%  
FIIs % 16.8 23.7 70.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 36.1 26.2 137.8%  
Shareholders   16,479 161,166 10.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS